The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas. Congress materials may include information for which the product is not approved.
Diabetes, Obesity and Metabolism, March 2026
Prevalence of Cardiovascular-Kidney-Metabolic Conditions Across Body Mass Index Categories: The Distinct Burden of Severe (Class III) Obesity
S. S. Rathore, K. C. Chung, Y. B. Akkas, A. J. Epstein, and B. Lian, “Prevalence of Cardiovascular-Kidney-Metabolic Conditions Across Body Mass Index Categories: The Distinct Burden of Severe (Class III) Obesity,” Diabetes, Obesity and Metabolism (2026): 1–4, https://doi.org/10.1111/dom.70628.
Obesity, January 2026
Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study
H. E. Bays, P. Toth, N. Alkhouri, et al., “Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study,” Obesity (2026): 1–13, https://doi.org/10.1002/oby.70106.
American Heart Association, November 2025
VANQUISH-2: Phase 3, Randomized, Double-blind, Placebo-controlled, Trial of weekly subcutaneous administration of VK2735 in Obese or Overweight Adults with Type 2 Diabetes
Modesto K, Chung K, Ji S, et al. VANQUISH-2: Phase 3, Randomized, Double-blind, Placebo-controlled, Trial of weekly subcutaneous administration of VK2735 in Obese or Overweight Adults with Type 2 Diabetes (2025). Circulation, 152. suppl_3.4367152. DOI:10.1161/circ.152.suppl_3.4367152
American Heart Association, November 2025
Prevalence of cardiometabolic conditions across body mass index categories—the distinct burden of severe (class III) obesity
Rathore S, Chung K, Akkas Y, et al. Prevalence of cardiometabolic conditions across body mass index categories—the distinct burden of severe (class III) obesity (2025). Circulation, 152. suppl_3. 47361241. https://doi.org/10.1161/circ.152.suppl_3.4361241
Obesity Week, November 2025
Impact of Subcutaneous VK2735 on Weight, Prediabetes, and Cardiometabolic Status: The VENTURE Study
Bays H, Freilich B, Hedges P, et al. Impact of Subcutaneous VK2735 on Weight, Prediabetes, and Cardiometabolic Status: The VENTURE Study (2025), Poster Abstracts. Obesity (Silver Spring), 33: 410-411. https://doi.org/10.1002/oby.70103
Obesity Week, November 2025
VANQUISH-1 Design: Phase 3 Trial of Subcutaneous VK2735 in Adults with Overweight or Obesity
Modesto K, Ji S, Stubbe S, et al. VANQUISH-1 Design: Phase 3 Trial of Subcutaneous VK2735 in Adults with Overweight or Obesity (2025), Poster Abstracts. Obesity (Silver Spring), 33: 235. https://doi.org/10.1002/oby.70103
ISPOR, May 2025
Obesity Impact on Incidence of Chronic Comorbid Conditions
Chung K, Mancini M, Modesto K, et al. Obesity Impact on Incidence of Chronic Comorbid Conditions (2025), Value in Health, Volume 28, Issue 6, S42. DOI: 10.1016/j.jval.2025.04.192
Obesity Week, November 2024
First-in-Human Study of an Oral Formulation of the GLP-1/GIP Co-Agonist VK2735 in Healthy Adults
Neutel J, Rowland A, Bell F, et al. First-in-Human Study of an Oral Formulation of the GLP-1/GIP Co-Agonist VK2735 in Healthy Adults (2024). Obesity (Silver Spring), 32: 61-62. https://doi.org/10.1002/oby.24195
Obesity Week, November 2024
Results From the 13-Week VENTURE Phase 2a Study of the GLP-1/GIP Co-Agonist VK2735 in Obese Patients
Neutel J, Alkhouri N, Bays H, et al. Results From the 13-Week VENTURE Phase 2a Study of the GLP-1/GIP Co-Agonist VK2735 in Obese Patients (2024). Obesity (Silver Spring), 32: 62. https://doi.org/10.1002/oby.24195
